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respectively.  Conclusion: In our cohort, patients with bilater-
ally positive biopsy cores were significantly more likely to 
harbor a non-organ-confined tumor than patients with uni-
laterally positive cores. Due to their high specificity, bilater-
ally positive biopsies may represent a reasonable exclusion 
criterion for active surveillance if our results are corroborat-
ed in further studies.  © 2014 S. Karger AG, Basel 
 Introduction 
 Screening for prostate cancer (PCa) has been shown 
to reduce disease-specific mortality  [1] ; it is, however, 
associated with significant overtreatment due to the de-
tection of many indolent tumors (i.e. tumors which 
would never become clinically manifest and which 
would never harm the patient even if left untreated)  [2] . 
In an effort to reduce this overtreatment, more and more 
PCa patients are included in active surveillance (AS) 
programs. Candidates for this strategy are patients who 
are most likely to harbor insignificant (i.e. low-volume, 
non-aggressive PCa) disease. Available evidence sug-
gests that this strategy is a viable alternative to immedi-
ate treatment  [3, 4] . However, underestimation of the 
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 Abstract 
 Purpose: To investigate the association between the lateral-
ity of diagnostic prostate cancer-positive biopsy cores and 
definitive tumor stage on final pathology (organ-confined 
versus non-organ-confined).  Patients and Methods: This is 
a retrospective analysis of 165 men after radical prostatec-
tomy fulfilling our active surveillance criteria at the time of 
surgery. Nominal variables were compared using Fisher’s 
 exact test, continuous variables using Mann-Whitney test. 
Odds ratios including 95% Wald and probabilities includ-
ing 95% Wilson confidence intervals are provided.  Results: 
5 (3%) patients had non-organ-confined disease: 2 out of 144 
(1%) patients with unilateral and 3 out of 17 (18%) patients 
with bilateral cancer-positive biopsy cores (p = 0.009). The 
estimated odds ratio for non-organ-confined disease was 
14.67 (95% confidence interval 1.55–189.23) for patients 
with bilateral compared to patients with unilateral cancer-
positive biopsy cores. The sensitivity, specificity and accu-
racy of bilaterally positive biopsies as an additional criterion 
to identify non-organ-confined disease are 60, 91 and 90%, 
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tumor burden and subsequent undertreatment of sig-
nificant PCa is an obvious concern of the AS strategy. 
Additional parameters to predict indolent PCa more ac-
curately would therefore be desirable, as long as they are 
specific enough not to falsely exclude too many indolent 
cancers. In the absence of more reliable predictors, the 
number of PCa-positive biopsy cores and the extent of 
PCa in the respective cores are most often used as sur-
rogate parameters for tumor volume. Current AS proto-
cols accept up to one positive biopsy core out of three 
cores taken as an inclusion criterion  [5] . Patients with up 
to two positive biopsy cores are accepted in the vast ma-
jority of AS cohorts, regardless of the distance between 
the two positive cores  [4, 6] . Indeed, this distance is very 
difficult to ascertain in clinical practice and is therefore 
generally not useful as an additional proxy parameter for 
tumor volume. It is, however, conceivable that a patient 
with one positive core from each side of the prostate has 
on average a larger tumor volume than a patient with 
positive biopsies only from one side of the prostate. The 
goal of this study was to evaluate whether non-organ-
confined disease is more prevalent if a prostate biopsy is 
positive bilaterally versus only unilaterally among pa-
tients eligible for AS.
 Patients and Methods 
 We retrospectively investigated the data of all patients who un-
derwent radical prostatectomy at the University Hospital of Zu-
rich, Switzerland, from 1999 to 2009 and fulfilled our current AS 
inclusion criteria (clinically organ-confined disease, PSA <10 ng/
ml, no Gleason pattern 4 or 5,  ≤ 2 positive biopsy cores) at the time 
of surgery. In these patients, the location of PCa-positive biopsy 
cores (unilateral versus bilateral) was associated with the final pa-
thology results. This study was conducted in accordance with the 
local ethical rules for retrospective studies.
 The primary outcome was the odds and odds ratio (as a mea-
sure of the relative risk) of having non-organ-confined disease be-
tween patients with only one PCa-affected prostatic lobe (unilat-
eral disease, irrespective of whether one or two biopsy cores were 
affected by PCa) and patients with bilaterally positive biopsies (one 
cancer-positive biopsy core on each side). The secondary outcome 
was the odds and odds ratio (as a measure of the relative risk) in 
the subset of patients with two PCa-affected biopsy cores, compar-
ing bilaterally PCa-positive patients (one PCa-positive biopsy core 
in each prostatic lobe) against unilateral PCa-positive patients 
(two PCa-positive cores within one prostatic lobe).
 Statistical Analysis 
 Nominal variables were compared using Fisher’s exact test and 
continuous variables using Mann-Whitney test. Odds ratios in-
cluding 95% Wald confidence intervals (CIs) computed on the 
logit scale are provided where suitable. Probabilities were estimat-
ed by calculating relative frequencies. The estimated proportions 
were completed with a 95% Wilson CI. All tests were performed at 
a significance level of α = 0.05 and CIs were computed using a con-
fidence level of 95%. All analyses were done using the R statistical 
software (R Development Core Team, 2012).
 Results 
 We identified 165 patients fulfilling our AS criteria at 
the time of radical prostatectomy. Complete information 
with regard to the location of cancer-positive biopsy cores 
was available in 161 patients; these 161 patients were 
 included in the analysis. Out of these 161 patients, 144 
had unilaterally PCa-positive biopsy cores; the remaining 
Table 1.  Patient characteristics
Overall Unilateral Bilateral Significance
Number of patients 161 144 17  
Age at operation, mean/median (range) 62/63 (43 – 76) 62/63 (43 – 76) 62/64 (49 – 72) 0.91*
PSA at operation, mean/median (range) 5.2/5 (0.6 – 9.2) 5.2/5 (0.6 – 9.2) 5.1/5 (2.6 – 8.6) 0.84*
Number of biopsy cores taken, mean/median (range) 8.7/8 (4 – 14) 8.7/8 (4 – 14) 8.5/8 (8 – 13) 0.74*
Biopsy Gleason score, number of patients     
<6 24 (15%) 20 (14%) 4 (24%) 0.29**6 137 (85%) 124 (86%) 13 (76%)
Final Gleason score, number of patients     
<7 105 (65%) 96 (67%) 9 (53%) 0.26**≥7 56 (35%) 48 (33%) 8 (47%)
 Overview over the main patient characteristics in the overall group and the subgroups of patients with unilaterally or bilaterally PCa-
positive biopsy cores. Significance was tested using t test for continuous and Pearson’s χ2 test for categorical variables. * t test; ** Pear-
son’s χ2 test.
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17 patients had bilaterally PCa-positive biopsy cores. The 
main patient characteristics of the overall group and the 
subgroups are summarized in  table 1 .
 Further, out of these 161 patients, 5 (3%) had >pT2 
(non-organ-confined) disease on final pathology. Only 
2 out of the 144 patients with unilaterally positive biopsy 
cores had >pT2 disease, representing a proportion of 1% 
(95% CI 0.00–0.05), whereas 3 out of the 17 patients with 
bilaterally positive biopsy cores had >pT2 disease, repre-
senting a proportion of 18% (95% CI 0.06–0.41) ( ta-
ble 2 ). Comparison with respect to laterality of PCa-pos-
itive biopsy cores showed a high statistical significance 
(p = 0.009). The estimated odds ratio for non-organ-
confined disease in bilaterally positive patients com-
pared to unilaterally positive patients was 14.67 (95% CI 
1.55–189.23). Out of the subset of 57 patients with two 
PCa-affected biopsy cores, 3 (5%) had >pT2 disease on 
final pathology. Here, none of 40 patients with unilater-
ally PCa-positive biopsy cores had >pT2 disease, repre-
senting a proportion of 0% (95% CI 0.00–0.09), whereas 
3 out of 17 patients with bilaterally PCa-positive biopsy 
cores had >pT2 disease, representing a proportion of 
18% (95% CI 0.06–0.41). The calculation of the odds ra-
tio reached infinity due to zero false-negative observa-
tions. The comparison with respect to laterality of PCa-
positive biopsy cores was statistically significant (p = 
0.02) ( table 3 ).
 Adding laterality of positive biopsy cores as a further 
inclusion or exclusion criterion to our AS protocol ended 
in a moderate to good sensitivity of 60% (3 out of 5), a 
very good specificity of 91% (142 out of 156) as well as a 
high overall accuracy of 90% (145 out of 161) for the iden-
Table 2.  Preoperative biopsy results versus postoperative pT status in the overall group
Preoperative
biopsy findings
Final stage pT  Comparison
≤pT2 >pT2 total proportion
of >pT2
 p odds ratio (95% CI)
Biopsy side       
Unilateral 142 2 144 1% 0.009 14.67 (1.55 – 189.23)Bilateral 14 3 17 18%
Total 156 5 161 3%   
 Cross tabulation of preoperative biopsy results concerning laterality of PCa-positive cores versus postopera-
tive final PCa stage in the overall group. Indicated is the number of patients, the proportions, the p value (Fisher’s 
exact test) as well as the odds ratio with 95% confidence interval.
Table 3. Preoperative biopsy results versus postoperative pT status in the subgroup of patients with two positive 
biopsy cores
Preoperative
biopsy findings
Final stage pT  Comparison
≤pT2 >pT2 total proportion
of >pT2
 p odds ratio (95% CI)
Biopsy side       
Unilateral 40 0 40 0% 0.02 (∞)Bilateral 14 3 17 18%
Total 54 3 57 5%   
Cross tabulation of preoperative biopsy results concerning laterality of PCa-positive cores versus postopera-
tive final PCa stage in patients with two PCa-positive biopsy cores preoperatively. Indicated is the number of 
patients, the proportions, the p value (Fisher’s exact test) as well as the odds ratio with 95% confidence interval. 
Due to zero false-negative observations the odds ratio reaches infinity.
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tification of non-organ-confined PCa. Sensitivity, speci-
ficity and accuracy in the subset of patients with two PCa-
positive biopsy cores only were 100% (3 out of 3), 74% (40 
out of 54) and 75% (43 out of 57), respectively.
 Discussion 
 In this study, we evaluated whether non-organ-con-
fined disease is more prevalent if a prostate biopsy is pos-
itive bilaterally versus only unilaterally among patients 
otherwise eligible for AS according to common AS pro-
tocols. We showed that patients with bilaterally positive 
prostate biopsy cores compared to patients with only 
unilaterally affected cores are indeed at a statistically sig-
nificantly higher risk of harboring locally advanced dis-
ease whereby the odds (as an estimate of risk) for non-
organ-confined disease are 14.67 times greater in bilater-
ally positive patients compared to unilaterally positive 
patients.
 Accurate risk stratification at the time of PCa diagno-
sis is crucial for an optimal treatment choice maintaining 
the right balance between adequate cancer control on the 
one side and therapy-related side effects on the other. 
Hence, additional parameters predicting indolent PCa 
more accurately are very desirable in order to make the 
AS strategy as safe as reasonably possible. However, such 
additional parameters need to be specific enough not to 
exclude a significant number of patients from the AS 
strategy by mistake. The laterality of PCa-positive biopsy 
cores (unilaterally versus bilaterally positive cores) as an 
additional selection parameter for AS patients showed 
this specific characteristic within our study. Whereas 60% 
of all non-organ-confined PCa cases could have been pre-
dicted, the vast majority (about 90%) of the initially se-
lected men would still have qualified for AS. In compari-
son, using a different PSA cut-off value to detect non-
organ-confined disease with the same sensitivity as the 
laterality variable would need a lowering of the cut-off 
point to 5.6 ng/ml. This would be accompanied by a spec-
ificity of 61%, representing a 30% absolute difference 
compared to the specificity of the laterality variable. 
Hence, due to this high specificity of the laterality vari-
able, bilaterally positive biopsies may represent a reason-
able exclusion criterion for AS. However, due to the lim-
itations of our study the results must be corroborated in 
further studies.
 Formerly, Raventós et al.  [7] also reported about the 
predictive ability of laterality (unilateral versus bilateral) 
of PCa-affected biopsy cores in the prediction of patho-
logically insignificant PCa as defined by tumor volume 
<0.5 cm 3 and Gleason score  ≤ 6 in radical prostatectomy 
specimens. They used a retrospective study design in a 
group of 280 patients; 108 patients (38.3%) were at low 
risk amongst the criteria of D’Amico  [8] (PSA  ≤ 10 ng/ml 
and Gleason Score <7 and cT1–2a) at the time of surgery. 
The association with laterality was observed in the overall 
group as well as in the low-risk group. Focusing on the 
low-risk group, the percentage of patients with bilaterally 
positive biopsy cores was only 4.3% in the group of pa-
tients with insignificant disease in final pathological find-
ings, whereas the percentage was 26.2% in the group with 
significant disease in final pathological findings (p = 
0.024). However, in logistic regression the predictive abil-
ity of laterality disappeared whereas the number of posi-
tive cores remained as a predictive variable. Our study 
design is in analogy to the one of Raventós et al.; however, 
there are two main differences. First, our study popula-
tion was different and much more specifically defined ac-
cording to our current AS criteria. Thus, the low-risk 
group in the study of Raventós et al. was older on average 
(mean age 65.2 years, range 36.1–76.2) and had higher 
PSA values (mean 6.6 ng/ml, range 4.1–9.7). The overall 
number of biopsy cores taken was not specified for the 
low-risk group, the mean and median of total cores taken 
in the overall group, however, were 7.4 and 6. The num-
ber of positive cores in the low-risk group ranged from 1 
to 7, whereas in our cohort none of the patients had more 
than two positive biopsy cores. Second, our outcome was 
much more specific and focused on tumor volume assess-
ment. This is crucial since we assume that the variable 
laterality fits with tumor volume and not tumor aggres-
siveness, hence a combined outcome as used by Raventós 
et al. may be suboptimal. These differences in study pop-
ulation and outcome definition could be crucial when 
comparing the results from our study to the one of 
Raventós et al.
 Several aspects of our study require discussion. This is 
a retrospective analysis performed within a group of pa-
tients after radical prostatectomy fulfilling all criteria for 
AS at the time of surgery. Obviously, the data set was orig-
inally not designed to answer our specific research ques-
tion. Hence, the number of patients, or the number of 
observations, respectively, is relatively low. This also be-
comes evident in the broad 95% CI, reflecting the uncer-
tainty due to the small number of observations. However, 
the very low rate of non-organ-confined disease (>pT2) 
in our cohort underscores how effective our selection cri-
teria for AS patients already are. The fact that a very sim-
ple additional selection parameter shows a specificity of 
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>90% in this scenario is in itself remarkable. Moreover, it 
may be that our retrospective study cohort is not repre-
sentative; however, it is not a selection, but rather a con-
secutive subset of patients out of a consecutive radical 
prostatectomy cohort between 1999 and 2009 fulfilling 
our current AS criteria at the time of surgery.
 An additional limitation of our study is that data about 
the amount of cancer involvement (usually indicated as 
percentage) within a PCa-affected biopsy core were un-
available within our data set; this criterion was shown to 
be very useful as a surrogate in the assessment of the real 
cancer volume. However, since this is a retrospective 
analysis, we have to take into consideration that histori-
cally the percentage of cancer-affected volume within one 
biopsy core was not routinely associated with an indica-
tion of biopsy core length; hence, the pure evaluation of 
percentage of cancer involvement per core would have 
been a difficult parameter within this cohort anyhow. 
Four patients (2%) had missing data, so that only 161 out 
of 165 patients were entered into our analysis.
 Furthermore, it may be that the two groups (unilater-
ally versus bilaterally cancer-positive biopsy cores) dif-
fered in other variables than the laterality of positive bi-
opsy cores and that this led to confounding. However, we 
found no statistically significant differences in important 
patient characteristics as shown in  table 1 ; a more sophis-
ticated comparison using additionally PSA density as well 
as the assessment of the association with real tumor vol-
ume in the final pathology specimen was not possible due 
to unavailable corresponding data in our data set. Fur-
ther, due to very few patients with biopsy core sample 
numbers below 8 (n = 7; 4 patients with 6 biopsy cores, 1 
patient with 5 biopsy cores and 2 patients with 4 biopsy 
cores only) we may reasonably assume that the group of 
patients with unilaterally PCa-positive biopsy cores is not 
undersampled compared to the group of patients with bi-
laterally PCa-positive biopsy cores. However, we lack the 
information about why these unusually low numbers of 
biopsy cores were taken during the diagnostic work-up. 
At our institution, in earlier years an 8–12- and currently 
a 12-core biopsy protocol is standard in the diagnostic 
work-up; however, we did not perform a confirmation 
biopsy in all of the patients with an out-of-hospital diag-
nosis of PCa by a low number of biopsy cores sent to our 
department for treatment. In the end, the population un-
der investigation already represents a very well-defined 
subset of PCa patients, which decreases the potential for 
confounding upfront.
 Lastly, for our primary outcome we compared men 
with two positive biopsy cores (one on each side of the 
prostate) to men with either one or two positive biopsy 
cores (just on one side). Thus, it could be argued that our 
results simply reflect the comparison of different num-
bers of positive cores rather than laterality of the positive 
cores. However, the effect remained statistically signifi-
cant even in the subgroup analysis of only patients with 
two positive cores. However, due to zero false-negative 
observations the size of the effect could not be assessed in 
this subgroup, nor could we do a meaningful regression 
analysis adjusting for the number of positive cores due to 
the limited number of observations. A larger number of 
patients will be needed to assess the amount of the effect 
and to narrow the CIs and as such to improve the accu-
racy of the results.
 In summary, using the variable laterality as an addi-
tional criterion to our current AS criteria results in a 
moderate to good sensitivity for identifying non-organ-
confined disease on final pathological findings upfront 
and reduces undertreatment – an obvious concern in AS 
patients – by decreasing misclassification in our cohort 
relatively by 60% (2 compared to 5 misclassified men) and 
absolutely by 2% (2 compared to 5 misclassified men out 
of 161). The fact that the rate of non-organ-confined and 
as such misclassified disease cases (>pT2) in our cohort is 
already very low with only 3% makes the additional obvi-
ous improvement by adding one very simple additional 
selection parameter indeed remarkable, especially since 
the corresponding specificity remains over 90%. Never-
theless, the prize to pay for this additional safety is the 
finally unnecessary exclusion of men who actually would 
qualify for AS due to decrease – even only slightly – in 
specificity (minus 9%); this in turn results in overtreat-
ment. However, in our cohort overall only two men would 
have been affected hereby, representing relatively as well 
as absolutely a little more than 1% of all men in our co-
hort. Hence, by applying the additional parameter lateral-
ity to our current AS criteria, the relation between risk 
reduction of undertreatment and overtreatment seems 
beneficial for its use. Taking all the limitations of our 
study into account and against the background that cur-
rently various protocols for AS inclusion and exclusion 
exist, we understand our findings much more as a hint 
than proof for the usefulness of the bilaterality variable in 
AS.
 In conclusion, in our study of PCa patients eligible for 
AS amongst our current criteria, patients with bilaterally 
positive biopsy cores were significantly more likely to 
harbor a non-organ-confined tumor than patients with 
unilaterally positive cores only. Laterality of positive bi-
opsy cores showed a very good specificity of 91% for the 
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identification of non-organ-confined PCa. Due to this 
high specificity, bilaterally positive biopsies may repre-
sent a reasonable exclusion criterion for AS if our results 
are corroborated in further studies.
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